Saturday 17 October 2026
Export MASS’s income statement to Excel — free account
908 Devices Inc.
MASS Healthcare Medical Devices
In the quarter to June 2026, revenue grew 23.3%, EPS grew 13.5% and free cash flow grew 151.0%, each against the same quarter a year earlier.
11.33
0.56
−4.71%
Follow MASS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 9.38 | 0.00 | 0.00 |
P/S ratio |
5.95 | 3.35 | 3.90 | 5.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 533.71 | |
P/Operating CF |
(75.22) | 142.89 | 187.00 | 103.51 | |
P/B ratio |
2.32 | 1.31 | 1.68 | 2.59 | |
Price to Tangible BV |
3.19 | 1.76 | 2.29 | 4.65 | |
EV/Sales |
4.13 | 1.62 | 2.23 | 3.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.06) | (3.84) | (17.30) | 162.44 | |
EV/FCF |
(7.74) | (3.69) | (15.55) | 393.83 | |
Quick Ratio |
2.97 | 3.65 | 3.07 | 2.29 | |
Current Ratio |
3.49 | 4.24 | 3.58 | 2.67 | |
Net Debt/EBITDA |
7.23 | (26.87) | 9.66 | 8.92 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.32 | 0.30 | 0.31 | |
Operating CF/Net income |
0.28 | 0.32 | (0.10) | (0.27) | |
Capex/Depreciation |
(0.81) | 0.01 | (0.03) | (0.11) | |
Research and Development Expense of Revenue |
27.40% | 20.16% | 25.94% | 22.38% | |
Selling, General and Administrative Expense of Revenue |
65.22% | 50.74% | 74.09% | 69.13% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.19 | 0.28 | |
Share Based Compensation of Revenue |
16.99% | 15.91% | 17.93% | 14.39% | |
Graham Net Nets |
0.29 | 0.52 | 0.40 | 0.19 | |
Graham Number |
0.00 | 7.10 | 0.00 | 0.00 | |
Earnings Yield |
(1.26%) | 10.67% | (16.18%) | (10.80%) | |
Free Cash Flow Yield |
(8.98%) | (13.08%) | (3.68%) | 0.19% | |
Revenue per Share |
0.39 | 0.48 | 0.36 | 0.43 | |
Operating CF per Share |
(0.12) | 0.04 | 0.03 | 0.08 | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | 0.04 | 0.03 | 0.08 | |
Cash per Share |
3.10 | 3.15 | 3.03 | 2.69 | |
Shareholders Equity per Share |
3.78 | 4.00 | 3.64 | 3.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.78 | 4.00 | 3.64 | 3.36 | |
Free Cash Flow |
(4.88) | 1.33 | 1.17 | 3.01 | |
Working Capital |
103.46 | 110.50 | 102.35 | 82.60 | |
Capital Expenditures |
(0.68) | 0.01 | (0.04) | (0.16) | |
Net Current Asset Value |
90.36 | 98.19 | 89.49 | 61.25 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.83 | 10.09 | 8.40 | 8.96 | |
Average Payables |
1.85 | 1.48 | 3.13 | 3.15 | |
Average Inventory |
16.58 | 11.94 | 12.99 | 14.92 | |
Average Assets |
184.58 | 174.77 | 191.36 | 194.62 | |
Average Common Equity |
133.67 | 129.15 | 146.80 | 137.79 |
Columns are period end dates